Ophthalmic IBM · Eye Drop Container · Korean KFDA · Korea Ever-Power

HDPE Eye Drop Bottle IBM:
Korean Production Guide

Korean 10 ml HDPE ophthalmic containers are the highest-volume pharmaceutical IBM format in Korea and one of the most technically demanding: dropper cap engagement precision at ±0.05 mm, fill-level transparency at 0.30–0.40 mm body wall, KFDA ophthalmic particulate compliance, and multi-hundred-million-unit annual volume requirements that place the ZQ110 and ZQ135 machines at the centre of Korean ophthalmic packaging production economics.

10 ml Cavity Count Economics
Dropper Cap Neck Precision
KFDA Ophthalmic Qualification

Korea Ever-Power Engineering Desk · Ansan-si · July 2026

Korean Ophthalmic IBM — Reference Data

10 ml

Standard Korean ophthalmic container — the IBM format with highest annual demand

500M+

Estimated Korean annual ophthalmic container demand — contact lens, dry eye, prescription

±0.05 mm

IBM neck OD tolerance — dropper cap engagement requires ±0.06 mm window

~23,800/h

ZQ135 at 30 cavities — highest single-machine Korean ophthalmic IBM output

1. Korean Ophthalmic Market and IBM’s Role

Korean HDPE ophthalmic eye drop bottles — 10ml injection blow molded pharmaceutical container with dropper cap 13/415 neck finish, 0.35mm body wall translucency for fill-level inspection, produced by Korea Ever-Power ZQ80 ZQ110 at 20-24 cavity Korean pharmaceutical ophthalmic IBM production for Korean KFDA ophthalmic container qualification — Korean pharmaceutical 10 ml HDPE ophthalmic containers produced by injection blow molding — showing the 13/415 dropper neck finish with ±0.05 mm OD tolerance for dropper cap engagement, the 0.30–0.40 mm body wall that allows translucent fill-level inspection, and the injection-moulded base without seam or gate witness mark visible from the exterior. At 20–30 cavities per cycle, IBM is the only blow molding process that produces Korean ophthalmic volumes at pharmaceutical quality and economic scale simultaneously.

Korea’s ophthalmic pharmaceutical market is among the largest and fastest-growing in East Asia. Three structural factors drive Korean ophthalmic container demand above what Korea’s population size alone would suggest: the world’s highest rate of contact lens wear per capita (approximately 42% of Korean adults aged 20–40 wear contact lenses, generating daily artificial tear and contact lens solution demand), the exceptionally high Korean screen time (Korean workers average 9.4 hours per day of screen exposure, driving rapidly growing dry-eye disease prevalence), and Korea’s nationally covered ophthalmic prescription reimbursement system (Korean National Health Insurance covers most ophthalmic prescription medications, lowering the price barrier to ophthalmic pharmaceutical use). These three factors together produce an estimated 500+ million annual ophthalmic container demand in Korea, split between prescription ophthalmic (antibiotics, anti-inflammatory, antiglaucoma), OTC artificial tears, and contact lens care products — all requiring 10 ml HDPE IBM containers.

IBM is the Korean ophthalmic container process standard because the 10 ml ophthalmic format uniquely benefits from every IBM technical advantage simultaneously: injection-moulded neck at ±0.05 mm (dropper cap engagement requires ±0.06 mm), zero flash (KFDA ophthalmic particulate compliance), multi-cavity output up to 30 cavities (production economics at 500M+ unit annual demand), and translucent HDPE body wall at 0.30–0.40 mm (fill-level inspection without transparency requirements). No other blow molding process delivers all four advantages at the 10 ml format. The broader context of IBM for Korean pharmaceutical production is covered in the pharmaceutical IBM guide; this article focuses specifically on 10 ml HDPE ophthalmic container production.

2. 10 ml HDPE Ophthalmic Container Specifications

IBM 3-station process for 10ml ophthalmic HDPE container — Station 1 injection at 800-1350KN of 10ml preform with 13/415 dropper neck insert, Station 2 blow moulding to 25mm body diameter 45mm height, Station 3 stripping — 20-30 cavity simultaneous production on Korea Ever-Power ZQ80 ZQ110 ZQ135 for Korean ophthalmic pharmaceutical HDPE IBM production — IBM 3-station process applied to 10 ml ophthalmic container production — all three stations execute simultaneously, with 20–30 ophthalmic preforms being injection moulded at Station 1 while 20–30 bottles from the previous cycle are being blown at Station 2 and 20–30 finished bottles from the cycle before that are being stripped at Station 3. The concurrent execution is why IBM at 30 cavities achieves approximately 23,800 ophthalmic bottles per hour despite each station taking several seconds.

Korean 10 ml HDPE ophthalmic containers follow a remarkably standardised dimensional specification across Korean pharmaceutical brands — standardisation driven by compatibility with dropper cap systems supplied by Korean dropper cap manufacturers and by Korean pharmaceutical filling line specifications that are optimised for the standard 10 ml ophthalmic format dimensions.

Dimension	Specification	Function / Requirement Basis
Neck finish	13/415 GPI	Standard Korean ophthalmic dropper cap interface — compatible with Korean dropper cap and CRC ophthalmic cap suppliers
Neck OD tolerance	13.00 mm ±0.05 mm	Dropper cap snap-fit engagement tolerance window — IBM native, ±0.05 mm across all cavities
Bore ID	9.0 mm ±0.04 mm	Dropper insert outer diameter engagement — defined by core rod OD in IBM injection mould
Container height	42–52 mm	Korean filling line gripper compatibility and Korean pharmacy dispensing tray dimension
Body max diameter	22–28 mm	Korean pharmacy dispensing unit-dose tray row spacing — max 28 mm for standard Korean tray compatibility
Body wall thickness	0.30–0.40 mm	Translucency for fill-level inspection; ≤0.40 mm for sufficient HDPE translucency at 10 ml volume
Volume accuracy	10.0 ml ±0.5 ml	Korean KFDA ophthalmic fill volume tolerance — fill mark position on IBM container must reflect this tolerance at 23°C
Bottle weight	2.5–4.5 g	HDPE IBM at 0.30–0.40 mm body wall — lighter than EBM equivalent; cavity-to-cavity weight CV% ≤4% specification

The 13/415 neck finish specification is critical for Korean ophthalmic IBM mould design: the 13 mm nominal neck OD and 415 thread count (15 threads per inch) are the international standard for ophthalmic dropper closures adopted by Korean ophthalmic pharmaceutical brands and Korean dropper cap manufacturers. IBM container moulds for Korean ophthalmic production must specify 13/415 neck inserts in the injection mould to the same dimensional accuracy as the Korean dropper cap tooling — ±0.02 mm on the neck OD at the injection mould neck cavity insert ensures that the finished IBM bottle’s ±0.05 mm neck OD tolerance is achieved with process margin on both sides of the dropper cap engagement window.

3. IBM Neck Precision for Dropper Cap Engagement

IBM injection blow molding mould precision — 13/415 ophthalmic neck insert in injection mould core rod assembly showing ±0.02mm neck OD cavity tolerance producing ±0.05mm IBM bottle neck OD across all 20-30 production cavities — Korea Ever-Power pharmaceutical ophthalmic mould S136 stainless steel neck insert for Korean KFDA ophthalmic dropper cap engagement qualification — IBM ophthalmic neck precision — the injection mould’s 13/415 neck insert (S136 stainless, HRC 50–52) defines the ophthalmic container neck at ±0.02 mm cavity dimensional tolerance, producing ±0.05 mm neck OD on finished IBM bottles across all 20–30 production cavities. The core rod holds the 9.0 mm bore ID throughout both injection and blow phases, ensuring the dropper insert engagement diameter is identical to the injection mould’s core rod OD regardless of blow air pressure variation between cycles.

The Korean ophthalmic dropper cap system has two precision interface points with the IBM container neck: the outer snap-fit or thread engagement between the dropper cap skirt and the neck OD, and the inner bore engagement between the dropper insert’s controlled orifice body and the neck bore ID. Both interfaces require dimensional precision that IBM provides natively through its injection mould tooling and core rod mechanism.

Outer Snap-Fit Interface: Neck OD ±0.05 mm

Korean ophthalmic dropper caps engage the IBM bottle neck at the 13 mm OD by a circumferential bead on the cap skirt that snaps over the neck’s retaining flange. This snap-fit engagement provides: tamper evidence (the bead breaks an induction seal or deforms the retaining flange on first opening), child resistance (some Korean ophthalmic CRC formats require push-and-turn action), and closure retention during Korean pharmacy dispensing handling (the cap must remain attached to the bottle when tapped on a Korean pharmacy dispensing tray). The snap-fit mechanism’s function depends on the interference between the cap bead inner diameter and the bottle neck flange OD — the designed interference is typically 0.08–0.15 mm (the cap bead is 0.08–0.15 mm smaller in diameter than the neck flange OD). With IBM’s ±0.05 mm neck OD tolerance, the interference varies between 0.08–0.15 mm ±0.05 mm across all cavities — always within the range where snap-fit engagement occurs without cap opening force being excessive for Korean pharmacists or patients. With EBM’s ±0.15–0.25 mm neck OD tolerance, the interference variation of ±0.15–0.25 mm would produce, at the low end, engagement that is either absent (cap falls off) or, at the high end, engagement that requires destructive force to open — neither acceptable in Korean ophthalmic pharmaceutical distribution.

Inner Bore Interface: Dropper Insert Orifice at ±0.04 mm

The dropper insert — the controlled-orifice component that produces a consistent 25–35 microlitre drop volume per squeeze — seats inside the IBM bottle neck bore, with its outer body in contact with the bore inner surface. The drop volume delivered by the dropper insert depends on two factors: the orifice diameter (controlled by the dropper insert mould tooling) and the bore-insert interference fit (controlled by the IBM bore ID versus the dropper insert OD). If the IBM bore is too small (below nominal), the dropper insert compresses inward and distorts the orifice geometry — producing smaller drop volumes than specified. If the IBM bore is too large (above nominal), the dropper insert can tilt within the bore, creating asymmetric orifice orientation that produces erratic drop trajectory in Korean patient use. IBM’s core rod defines the bore ID at ±0.04 mm across all cavities through the direct mechanical relationship between the core rod OD and the bore it forms during injection — the bore is not blown, not stretched, not dependent on air pressure, and does not vary with process parameter fluctuation at the blow station.

4. HDPE Grade and Processing for Ophthalmic IBM

Korean ophthalmic HDPE IBM uses a narrower resin specification than general pharmaceutical IBM — the combination of thin body wall (0.30–0.40 mm), high cavity count (20–30 cavities), long hot runner paths, and Korean KFDA extractables requirements creates a specification set that narrows the usable HDPE grade range to MI 0.3–0.5 at 190°C/2.16 kg and density 0.950–0.960 g/cm³ for the majority of Korean ophthalmic IBM applications.

Resin Grade Specification

MI: 0.3–0.5 g/10min (190°C / 2.16 kg)
Density: 0.950–0.960 g/cm³
Additives: KFDA positive list only
No UV stabilisers, no slip agents
Antioxidant: AO-1010 or AO-168 ≤0.05%
KFDA pharmaceutical contact declaration required

Processing Parameters (ZQ80/ZQ110)

Barrel: 175→195→210→215→215°C
Injection pressure: 90–130 MPa
Fill time: 0.6–1.0 s (thin wall)
Hold: 50–65% peak, 0.4–0.8 s
Blow air: 0.5–0.8 MPa
Blow dwell: 0.7–1.2 s
Mould temperature: 12–22°C

Critical Quality Checks

Neck OD: 13.00 ±0.05 mm — all cavities
Bore ID: 9.0 ±0.04 mm — all cavities
Bottle weight: ±4% CV% across cavities
Wall translucency: pass visual fill-level check
Dropper cap engagement: 100% snap-fit on line
Particulate: pass KFDA ophthalmic standard

Wall translucency and HDPE grade interaction: Korean ophthalmic containers must allow Korean pharmacists and Korean patients to visually inspect the liquid fill level — a requirement that limits HDPE wall thickness to ≤0.40 mm at the body panel, where HDPE’s semi-crystalline structure transmits sufficient light at this thickness for fill-level judgement. At 0.50 mm body wall, standard HDPE at density 0.955 g/cm³ becomes opaque enough that fill-level inspection is unreliable. The 0.30–0.40 mm body wall is a design constraint that the IBM mould designer must achieve through the preform geometry and blow ratio — and that the IBM operator must verify in production through periodic wall thickness measurement at the minimum body wall location using ultrasonic gauge measurement.

5. Korean KFDA Ophthalmic Container Qualification Requirements

Korean KFDA ophthalmic pharmaceutical container qualification requirements are more stringent than general pharmaceutical container requirements in two specific areas: particulate contamination standards and compatibility testing duration. These stricter requirements reflect the ophthalmic route of administration — the ocular surface is highly sensitive to particulate and chemical insults, and Korean KFDA ophthalmic product safety standards are calibrated accordingly.

Ophthalmic Particulate Standards (KFDA / Korean Pharmacopoeia)

Korean Pharmacopoeia (KP) aligns with USP <790> for visible particulates in ophthalmic preparations and USP <788> for sub-visible particulate matter in ophthalmic preparations. For Korean IBM ophthalmic container qualification, particulate testing applies in two stages: container wash-extract testing (empty containers filled with purified water, agitated and examined for visible particulate and sub-visible particulate count) and filled product testing (Korean ophthalmic formulation filled into IBM containers examined at end of proposed shelf life). IBM container wash-extract particulate limits per KP ophthalmic container test: visible particles — absent (zero visible particles in wash extract when examined under Korean Pharmacopoeia visible inspection method); sub-visible particles per KP (aligned with USP <788>): ≤25 particles/ml ≥10 μm, ≤3 particles/ml ≥25 μm. IBM’s zero-flash production eliminates the most significant source of sub-visible particulate in blow-moulded pharmaceutical containers — the plastic fines generated by EBM flash trimming. Korea Ever-Power’s pharmaceutical IBM documentation package includes a reference statement on IBM’s zero-flash architecture for use in the Korean pharmaceutical container qualification documentation that addresses Korean KFDA questions on particle contamination prevention during container production.

Compatibility Testing Duration for Ophthalmic IBM Containers

Korean KFDA ophthalmic pharmaceutical container compatibility testing requires a 24-month accelerated stability study at 40°C/75% RH — 12 months longer than the 12-month standard for most oral pharmaceutical container compatibility studies. The longer study period reflects the Korean KFDA position that ophthalmic formulations’ complex mixture of active ingredients, preservatives (benzalkonium chloride, thimerosal, or preservative-free buffer systems) and buffering agents creates a more complex extractable interaction profile with HDPE than simple aqueous solutions. Korean IBM ophthalmic packaging producers should plan for 24-month compatibility studies — which means beginning the filled container compatibility study immediately upon first IBM production at qualification conditions, so that the 24-month study result is available within the overall Korean ophthalmic product development timeline without delaying the KFDA submission.

6. IBM Cleanroom Setup for Korean Ophthalmic Production

Korea Ever-Power IBM ophthalmic pharmaceutical production line — ZQ series machine with HEPA positive-pressure cleanroom enclosure over mould area dual chiller mould temperature controllers oil-free air compressor output conveyor for Korean KFDA ophthalmic container production in ISO Class 8 cleanroom environment — Korea Ever-Power IBM ophthalmic production line components — the complete production cell for Korean KFDA ophthalmic container production includes the ZQ series machine with HEPA enclosure over the mould station and output conveyor, oil-free compressor (mandatory for ophthalmic-grade air supply), dual chiller for independent injection and blow mould temperature circuits, and HEPA-filtered output conveyor to maintained cleanliness through to the palletising station.

Korean ophthalmic IBM production is typically conducted in ISO Class 8 (Korean GMP Grade D equivalent) cleanroom environments. The specific cleanroom requirements for ophthalmic IBM container production — distinct from the general pharmaceutical IBM cleanroom setup described in the pharmaceutical IBM guide — reflect the higher particulate sensitivity of Korean ophthalmic containers.

HEPA supply air over mould station: The IBM machine’s mould area — where containers are formed and where the core rods deposit finished containers onto the output conveyor — should receive HEPA-filtered supply air at ≥0.45 m/s face velocity downward into the open mould area. This positive-pressure HEPA supply air prevents airborne particles from entering the open container mouth during the time between stripping (Station 3) and cap application at the downstream Korean pharmaceutical filling line. The HEPA enclosure over the mould station is specified as a separate engineering item in the Korean ophthalmic IBM cell design — Korea Ever-Power provides connection points and dimensional data for the HEPA enclosure installation on the ZQ machine outline drawings.
Oil-free compressed air — mandatory: Compressed air used for IBM blow moulding of Korean ophthalmic containers must be oil-free at the point of use — ISO 8573-1 Class 0 for oil aerosol and oil vapour. Oil contamination of the IBM blow air at the blow station contacts the interior of the HDPE preform during inflation and becomes an extractable contaminant in the finished container. Korean ophthalmic IBM producers must specify oil-free screw compressors (not oil-lubricated reciprocating compressors with downstream filters), and must verify oil-free status at the machine connection point with regular particulate and oil vapour monitoring per Korean pharmaceutical compressed air quality monitoring protocols.
Output conveyor HEPA enclosure: Korean ophthalmic containers exiting the IBM machine at Station 3 travel on an output conveyor before being collected into bags or trays for transport to the Korean pharmaceutical filling line. This conveyor section should also be HEPA-enclosed to maintain container cleanliness from the IBM machine exit to the collection point. The conveyor HEPA enclosure is typically installed as a tunnel with positive-pressure HEPA supply air and a filtered exhaust at the conveyor exit. Without conveyor enclosure, Korean ophthalmic IBM containers can accumulate airborne particulate during the conveyor transit that then settles into the open container mouth and contributes to sub-visible particulate counts in the filled container.

7. Cavity Count Economics for Korean Ophthalmic IBM

Cavity count selection for Korean ophthalmic IBM is the highest-impact single investment decision — because the Korean ophthalmic container market’s 500M+ annual unit demand requires matching machine cavity count to annual production volume with enough precision that the machine runs at 70–90% utilisation (below 60% utilisation wastes capital; above 90% utilisation creates production risk from unscheduled maintenance). The following analysis compares three ZQ models for a Korean ophthalmic contract packaging factory with a specific annual volume requirement.

Parameter	ZQ80 (20 cav)	ZQ110 (24 cav)	ZQ135 (30 cav)
Bottles/hour (88% eff.)	~15,840	~19,000	~23,760
Bottles/Korean 2-shift day (14 hr)	~221,760	~266,000	~332,640
Bottles/year (250 days)	~55.4M	~66.5M	~83.2M
Machines for 200M units/year	4 machines	3 machines	3 machines (72% util.)
KFDA qualifications required	4 machine quals	3 machine quals	3 machine quals (lowest per unit)

The cavity count economics table shows that for a Korean ophthalmic contract packager targeting 200M annual 10 ml units, the ZQ135 at 30 cavities requires the same number of machines as the ZQ110 at 24 cavities (3 machines in both cases) but runs at 72% utilisation versus 100% — providing production headroom for unscheduled maintenance, format change downtime, and annual demand growth without requiring a fourth machine purchase. The number of Korean KFDA machine qualifications is also minimised at the higher cavity count (3 qualifications at ZQ135 versus 4 at ZQ80) — each machine qualification represents 16–24 weeks of testing timeline and significant documentation cost. For Korean ophthalmic contract packaging facilities seeking to minimise their total number of KFDA machine qualifications while maintaining production redundancy, the ZQ135 or ZQ110 is clearly the correct investment over multiple ZQ80 machines at equivalent annual output. The Korea Ever-Power EP-ZQ110 is the most common starting platform for Korean ophthalmic contract packagers whose annual volume is in the 50M–80M unit range per machine.

8. ZQ Series Selection for Korean Ophthalmic IBM Production

For Korean ophthalmic IBM production, the selection between ZQ series models involves not just output rate and capital cost, but a pharmaceutical-specific consideration: the Korean KFDA qualification is tied to the specific machine model and cavity count. The following guidance accounts for this pharmaceutical-specific constraint.

Korean Ophthalmic Startup / Trial Production → ZQ60 (14 cavities)

Annual volume below 25M units. Korean pharmaceutical startup companies, Korean ophthalmic product line pilot runs, Korean CMO trial production for international ophthalmic brands entering Korea. The ZQ60 investment is appropriate for volumes below 25M units but requires careful future planning: upgrading from ZQ60 to ZQ80 for an existing KFDA-registered Korean ophthalmic product requires a new Korean KFDA machine change notification and qualification at the new machine — a 3–6 month process. Korean ophthalmic packaging producers who anticipate growing to 30M+ units within 3 years should commission ZQ80 from the start and accept the initial lower utilisation, avoiding the qualification transition cost.

Korean Mid-Scale Ophthalmic → ZQ80 (20 cavities, 30M–55M units/year)

The ZQ80’s dual hydraulic system (20–30% energy saving) and high-precision angle divider (standard at ZQ80+) make it the entry point for Korean ophthalmic production where energy efficiency and inter-cavity consistency are KFDA qualification requirements. At 20-cavity 10 ml production, ZQ80 produces approximately 55M ophthalmic bottles per Korean two-shift year — sufficient for Korean mid-scale pharmaceutical manufacturers serving Korean domestic ophthalmic market without export requirements.

Korean Large-Scale Ophthalmic → ZQ110 / ZQ135 (55M–83M+ units/year per machine)

Korean pharmaceutical contract packagers serving multi-national ophthalmic brands, Korean pharmaceutical exporters, and Korean national ophthalmic manufacturers serving Korean hospital supply chains at national scale — all require ZQ110 or ZQ135 production to achieve the output volumes and KFDA qualification efficiency that their business model demands. The full injection blow molding machine range covers all Korean ophthalmic production scales from startup to national-scale pharmaceutical supply.

Frequently Asked Questions

Q1 — What makes 10 ml ophthalmic IBM containers technically different from other pharmaceutical IBM containers?

10 ml ophthalmic IBM containers have four specific technical requirements that distinguish them from other pharmaceutical IBM containers. First, dual precision neck interface: ophthalmic containers require precision at both the outer neck OD (dropper cap snap-fit engagement at ±0.05 mm) and the inner neck bore (dropper insert orifice body at ±0.04 mm) simultaneously — most other pharmaceutical IBM containers require only outer neck OD precision for closure engagement. Second, body wall translucency: ophthalmic containers must allow visual fill-level inspection at 0.30–0.40 mm body wall — the thinnest wall specification in pharmaceutical IBM and one that requires specific preform design and blow ratio optimisation. Third, stricter particulate standards: Korean KFDA ophthalmic sub-visible particulate limits (≤25 particles/ml ≥10 μm) are more stringent than general pharmaceutical container particulate limits, requiring HEPA-enclosed production and oil-free compressed air at the IBM machine. Fourth, 24-month compatibility study: Korean KFDA ophthalmic container compatibility testing requires 24-month accelerated stability at 40°C/75% RH versus 12 months for most oral pharmaceutical containers — doubling the qualification timeline for the compatibility component. Together, these four characteristics make 10 ml ophthalmic IBM the most technically demanding standard pharmaceutical IBM format, and the format where Korea Ever-Power’s pharmaceutical IBM expertise provides the most value in guiding mould design, machine specification and qualification documentation preparation.

Q2 — Can the same IBM machine and mould produce both 10 ml and 15 ml ophthalmic containers?

Yes, but with important constraints. IBM moulds are specific to a container geometry — the injection mould, blow mould, and stripping tool are all designed and manufactured for a specific container shape, volume and neck finish. Running both 10 ml and 15 ml ophthalmic containers on the same IBM machine requires two separate mould sets (one per container format) with a mould change procedure between formats. The IBM machine is format-flexible by design: Korea Ever-Power’s ZQ series machines accommodate any mould set within the machine’s platen dimensions and shot weight range, so a ZQ80 qualified for 10 ml ophthalmic can also run a 15 ml ophthalmic mould set after a mould change. However, each container format requires its own Korean KFDA pharmaceutical container qualification — the 10 ml qualification does not extend to 15 ml because the container drawing, neck dimensions, volume and wall thickness all differ between formats. Korean pharmaceutical IBM producers who produce multiple ophthalmic formats on the same machine must maintain separate KFDA qualification documentation for each format, including separate cavit-by-cavity dimensional reports and separate compatibility test reports. Mould change time between ophthalmic IBM formats on the ZQ series is typically 3–5 hours for trained operators — the heaviest component of ophthalmic mould change is the 20–30 cavity injection mould assembly, which requires a floor-mounted crane rated for 80–150 kg (depending on cavity count) at the customer’s facility.

Q3 — How does Korean KFDA validate the IBM ophthalmic container’s dropper cap engagement across all cavities?

Korean KFDA pharmaceutical container qualification for ophthalmic dropper cap engagement is validated through three documented tests in the container technical file. First, dimensional compliance: all cavities must demonstrate neck OD within ±0.05 mm specification — verified by measuring 30 containers from each cavity across 3 production batches (90 measurements per cavity total) and confirming that all measurements are within specification with no outliers. Second, functional dropper cap engagement test: 200 containers are filled with distilled water, capped with the specified Korean dropper cap, and tested for: (a) cap retention under 10N axial pull force (simulating Korean pharmacist handling); (b) cap removal force within specification range (not so tight that patient opening requires excessive force); (c) dropper orifice drop volume 25–35 μl per drop as specified in the Korean pharmaceutical formulation requirement. Third, induction seal integrity (if applicable): containers sealed with induction foil are tested per ASTM F2096 bubble test, confirming hermetic seal across 100% of tested units. Korea Ever-Power provides pre-delivery functional dropper cap engagement test results from the production trial as part of the standard documentation package — Korean pharmaceutical brand QA teams can use these results as the first-batch functional test data in their KFDA container qualification technical file, reducing the time required to compile the qualification documentation after machine installation.

Q4 — What causes dropper cap retention failure in Korean ophthalmic IBM containers and how is it corrected?

Korean ophthalmic IBM container dropper cap retention failure — where the dropper cap separates from the bottle during Korean pharmacy dispensing handling or Korean patient use — has two root causes from the IBM container side. First, neck OD below specification minimum: if the IBM container neck OD is below 12.95 mm (13.00 mm nominal minus 0.05 mm tolerance minimum), the dropper cap’s retention bead does not engage the neck flange with sufficient interference — the bead slides over the flange without snapping into the retention groove, producing a container that appears capped but releases under minor handling force. Diagnostic: measure all cavities’ neck OD. If specific cavities are consistently below 12.95 mm, the problem is the injection mould neck insert for those cavities — either dimensional error in the insert or wear in the insert after extended production. Corrective action: regrind or replace the undersized neck cavity insert. Second, neck flange profile insufficiently defined: if the injection mould’s neck insert flange radius or flange height is below specification — typically from tool wear after 2–3 million cycles in a high-production ophthalmic mould — the dropper cap bead has no sharp flange edge to engage against, producing low retention force even when neck OD is within specification. Diagnostic: visual inspection of the neck flange profile under 10× magnification, comparing to the original mould drawing. Corrective action: neck insert regrind to restore flange sharpness (possible 2–3 times before insert replacement is required) or neck insert replacement. Korea Ever-Power’s mould service team provides neck insert inspection and regrind services for Korean ophthalmic IBM moulds under the machine’s standard service contract.

Q5 — How many ZQ110 machines does a Korean ophthalmic contract packager need to produce 300 million containers per year?

A Korean ophthalmic contract packager targeting 300 million 10 ml containers per year on ZQ110 machines (24 cavities, approximately 19,000 bottles per hour at 88% efficiency, approximately 66.5M containers per Korean two-shift year per machine) needs: 300M ÷ 66.5M ≈ 4.5 machines — in practice, 5 ZQ110 machines at 90% of capacity, or 4 ZQ110 machines at 113% of capacity (impossible without a third Korean shift). The practical recommendation for a 300M unit annual requirement on ZQ110 is 5 machines, giving 332.5M annual capacity at 90% utilisation — 10.8% headroom for unscheduled maintenance and demand growth. Five ZQ110 machines also require 5 Korean KFDA machine qualifications. An alternative — and commercially more efficient — approach for a 300M annual target is 4 ZQ135 machines: 4 × 83.2M = 332.8M annual capacity at 90% utilisation, with the same 5 million units headroom but only 4 KFDA machine qualifications (saving one qualification cycle). Korea Ever-Power’s application engineering team runs these comparative machine count analyses for Korean ophthalmic contract packaging facilities evaluating total cost of ownership, KFDA qualification cost and production flexibility between multiple ZQ110 and fewer ZQ135 configurations.

Q6 — Can Korean ophthalmic IBM containers be produced in pigmented (amber) HDPE for UV-sensitive formulations?

Yes, but pigmented Korean ophthalmic IBM containers require additional qualification steps versus natural HDPE ophthalmic containers. Amber HDPE for Korean ophthalmic IBM uses iron oxide-based amber masterbatch at 0.3–0.8% LDR in HDPE — iron oxide is on the Korean KFDA positive list for pharmaceutical packaging materials as an approved colourant. The pigment addition affects: extractables profile (additional extractables testing required for the pigmented grade versus natural HDPE — the amber masterbatch carrier resin and dispersion additives must be evaluated for Korean KFDA extractables compliance separately from the base HDPE resin); body wall translucency (amber pigment reduces visible light transmission further than natural HDPE at the same wall thickness, which is acceptable for UV-sensitive Korean ophthalmic formulations that require UV protection but means fill-level inspection must use a lightbox or specific lighting condition); and IBM processing (the masterbatch must be well-dispersed in the HDPE before IBM processing — poor dispersion creates visible pigment streaks in the amber bottle wall at the thin body panel zone, which is an appearance defect for Korean pharmacy dispensing). Korean ophthalmic pharmaceutical products that specify amber IBM containers typically include photosensitive Korean ophthalmic antibiotic preparations, certain Korean anti-inflammatory ophthalmic drops with UV-degradable active ingredients, and Korean ophthalmic diagnostic agents. The Korean pharmaceutical brand’s photostability data for the active ingredient (ICH Q1B photostability testing) should confirm whether an amber container is required or whether natural HDPE (which absorbs UV below 320 nm inherently at 0.35 mm wall) provides sufficient UV protection at the Korean ophthalmic product’s proposed storage conditions.

Ophthalmic IBM Enquiry

Planning Korean Ophthalmic Container IBM Production?

Korea Ever-Power provides 10 ml ophthalmic IBM mould design, Korean KFDA qualification documentation, cleanroom production cell planning and ZQ series machine selection for Korean ophthalmic pharmaceutical and OTC eye care packaging at all annual production volumes.

Request Ophthalmic IBM Consultation

Related Resources

Mid-Scale Ophthalmic IBM
EP-ZQ80 Injection Blow Molding Machine
800 KN · 20 cavities at 10 ml ophthalmic · Angle divider + dual hydraulic standard · ~55M Korean ophthalmic containers per Korean two-shift year.

Mega-Scale Ophthalmic IBM
EP-ZQ135 Injection Blow Molding Machine
1,350 KN · 30 cavities at 10 ml ophthalmic · 6+N barrel zones · 37+37 KW · ~83M Korean ophthalmic containers per year — Korean national hospital supply chain scale.

Material Guide
HDPE Injection Blow Molding: Complete Processing Guide
Full HDPE IBM processing guide — grade selection (MI 0.3–0.8), barrel temperature setup, wall thickness specification and ZQ series selection for pharmaceutical and household chemical IBM.

VR Tour of Our Factory

TAGs: